New long-term data on Calquence presented

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, have presented new, long-term follow-up results for Calquence (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma and updated results of an ongoing clinical trial assessing acalabrutinib monotherapy in treatment-naïve patients with chronic lymphocytic leukemia at ASH.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login